Goldenstone Acquisition Limited (GDST)

CTI BioPharma Income Statement

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Selling, General & Admin	0.97	0.72	1	0.04	0
Other Operating Expenses	-0.04	0.13	0.04	0.01	-
Operating Expenses	0.93	0.85	1.04	0.06	0
Operating Income	-0.93	-0.85	-1.04	-0.06	-0
Interest & Investment Income	1.33	2.93	1.48	0	-
EBT Excluding Unusual Items	0.4	2.09	0.45	-0.05	-0
Other Unusual Items	-	0.13	-	-	-
Pretax Income	0.4	2.21	0.45	-0.05	-0
Income Tax Expense	0.29	0.62	0.3	-	-
Net Income	0.11	1.6	0.15	-0.05	-0
Net Income to Common	0.11	1.6	0.15	-0.05	-0
Net Income Growth	-93.15%	997.21%	-	-	-
Shares Outstanding (Basic)	4	7	8	2	1
Shares Outstanding (Diluted)	4	7	8	2	1
Shares Change (YoY)	-41.93%	-4.88%	372.92%	28.50%	-
EPS (Basic)	0.03	0.22	0.02	-0.03	-
EPS (Diluted)	0.03	0.22	0.02	-0.03	-
EPS Growth	-88.20%	1053.58%	-	-	-
EBIT	-0.93	-0.85	-1.04	-0.06	-0
Effective Tax Rate	72.42%	27.85%	67.45%	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.